MASSIMI, DAVIDE
 Distribuzione geografica
Continente #
NA - Nord America 764
AS - Asia 401
EU - Europa 341
AF - Africa 123
SA - Sud America 95
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 6
Totale 1.737
Nazione #
US - Stati Uniti d'America 701
SG - Singapore 141
IT - Italia 82
CN - Cina 81
BR - Brasile 55
HK - Hong Kong 48
DE - Germania 36
RU - Federazione Russa 30
NL - Olanda 26
VN - Vietnam 23
FI - Finlandia 21
FR - Francia 18
GB - Regno Unito 15
BJ - Benin 13
IE - Irlanda 9
PH - Filippine 9
AT - Austria 8
CA - Canada 8
EC - Ecuador 8
JP - Giappone 8
PL - Polonia 8
AE - Emirati Arabi Uniti 7
LA - Repubblica Popolare Democratica del Laos 7
MG - Madagascar 7
ML - Mali 7
SE - Svezia 7
AR - Argentina 6
CO - Colombia 6
ES - Italia 6
IN - India 6
KE - Kenya 6
MR - Mauritania 6
AO - Angola 5
BB - Barbados 5
BY - Bielorussia 5
CW - ???statistics.table.value.countryCode.CW??? 5
HN - Honduras 5
LB - Libano 5
LV - Lettonia 5
MX - Messico 5
NE - Niger 5
NI - Nicaragua 5
SN - Senegal 5
TR - Turchia 5
BA - Bosnia-Erzegovina 4
BE - Belgio 4
BW - Botswana 4
CG - Congo 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
GE - Georgia 4
GR - Grecia 4
HR - Croazia 4
ID - Indonesia 4
JM - Giamaica 4
JO - Giordania 4
KR - Corea 4
KZ - Kazakistan 4
ME - Montenegro 4
MW - Malawi 4
NO - Norvegia 4
PE - Perù 4
PR - Porto Rico 4
PT - Portogallo 4
PY - Paraguay 4
RS - Serbia 4
RW - Ruanda 4
TW - Taiwan 4
AF - Afghanistan, Repubblica islamica di 3
AL - Albania 3
AZ - Azerbaigian 3
BF - Burkina Faso 3
BS - Bahamas 3
BZ - Belize 3
DM - Dominica 3
DZ - Algeria 3
EE - Estonia 3
EG - Egitto 3
GA - Gabon 3
GF - Guiana Francese 3
GM - Gambi 3
IR - Iran 3
MU - Mauritius 3
MZ - Mozambico 3
PK - Pakistan 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
SO - Somalia 3
TN - Tunisia 3
UA - Ucraina 3
VE - Venezuela 3
AU - Australia 2
BO - Bolivia 2
CI - Costa d'Avorio 2
CL - Cile 2
CY - Cipro 2
CZ - Repubblica Ceca 2
ET - Etiopia 2
GH - Ghana 2
GN - Guinea 2
Totale 1.662
Città #
Fairfield 101
Ashburn 99
Singapore 94
Chandler 77
Hong Kong 47
Beijing 36
Cambridge 33
Santa Clara 31
Seattle 30
Woodbridge 30
San Diego 26
Padova 24
Houston 21
Cotonou 13
Helsinki 13
Wilmington 13
Boardman 12
Medford 12
Princeton 12
Munich 11
Hanoi 10
Ann Arbor 9
Chicago 9
Des Moines 9
Ho Chi Minh City 9
Milan 9
Nuremberg 9
São Paulo 9
Roxbury 8
Bytom 7
Antananarivo 6
Los Angeles 6
Nairobi 6
Vientiane 6
Bamako 5
Bridgetown 5
Curtarolo 5
Lappeenranta 5
Luanda 5
Managua 5
Manila 5
Menlo Park 5
Minsk 5
Niamey 5
Nouakchott 5
Vienna 5
Amman 4
Amsterdam 4
Buffalo 4
Dakar 4
Dublin 4
Kigali 4
London 4
New York 4
Quito 4
Rome 4
Willemstad 4
Almaty 3
Baku 3
Bogotá 3
Boston 3
Brazzaville 3
Dallas 3
Denver 3
Falkenstein 3
Frankfurt am Main 3
Istanbul 3
Kingston 3
Kyiv 3
Libreville 3
Lilongwe 3
Maputo 3
Montreal 3
Moscow 3
Nassau 3
Podgorica 3
Pune 3
Riga 3
San Francisco 3
Sharjah 3
Verona 3
Washington 3
Abidjan 2
Accra 2
Addis Ababa 2
Athens 2
Baghdad 2
Banjul 2
Belgrade 2
Belize City 2
Belém 2
Bratislava 2
Brooklyn 2
Brussels 2
Budapest 2
Cabo Frio 2
Cairo 2
Cernusco sul Naviglio 2
Chevigny-Saint-Sauveur 2
Conakry 2
Totale 1.062
Nome #
Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis 184
Faecal microbiota transplantation in Clostridioides difficile infection: real-life experience from an academic Italian hospital 168
A specific microbiota signature is associated to various degrees of ulcerative colitis as assessed by a machine learning approach 166
REAL LIFE COMPARISON OF DIFFERENT ANTI-TNF BIOLOGIC THERAPIES FOR ULCERATIVE COLITIS TREATMENT: A RETROSPECTIVE COHORT STUDY 163
Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study 158
Fecal microbiota transplantation for norovirus infection: a clinical and microbiological success. 154
A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study 154
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator 147
Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation 129
Medical and gastroenterological education during the COVID-19 outbreak 114
Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study 114
Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity: A Cross-sectional Study 112
Totale 1.763
Categoria #
all - tutte 7.018
article - articoli 7.018
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.036


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202192 0 0 0 0 0 42 6 7 15 6 5 11
2021/2022235 14 16 27 7 17 40 17 4 30 18 11 34
2022/2023155 20 2 14 26 22 19 2 15 17 1 9 8
2023/2024131 10 13 15 10 14 17 15 11 2 4 11 9
2024/2025412 1 30 21 13 44 18 24 43 40 25 46 107
2025/2026690 93 109 209 232 47 0 0 0 0 0 0 0
Totale 1.763